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Abstract
Background: Tissue specificity is an important aspect of many genetic diseases in the context of genetic disorders
as the disorder affects only few tissues. Therefore tissue specificity is important in identifying disease-gene
associations. Hence this paper seeks to discuss the impact of using tissue specificity in predicting new disease-gene
associations and how to use tissue specificity along with phenotype information for a particular disease.
Methods: In order to find out the impact of using tissue specificity for predicting new disease-gene associations,
this study proposes a novel method called tissue-specified genes to construct tissues-specific gene-gene networks
for different tissue samples. Subsequently, these networks are used with phenotype details to predict disease genes
by using Katz method. The proposed method was compared with three other tissue-specific network construction
methods in order to check its effectiveness. Furthermore, to check the possibility of using tissue-specific gene-gene
network instead of generic protein-protein network at all time, the results are compared with three other methods.
Results: In terms of leave-one-out cross validation, calculation of the mean enrichment and ROC curves indicate
that the proposed approach outperforms existing network construction methods. Furthermore tissues-specific
gene-gene networks make a more positive impact on predicting disease-gene associations than generic protein-
protein interaction networks.
Conclusions: In conclusion by integrating tissue-specific data it enabled prediction of known and unknown
disease-gene associations for a particular disease more effectively. Hence it is better to use tissue-specific gene-
gene network whenever possible. In addition the proposed method is a better way of constructing tissue-specific
gene-gene networks.
Introduction
The emerging paradigm of “network medicine” has been
proposed to utilize different network-based approaches to
predict essential proteins [1-4], identify protein complexes
[5-8] and detect candidate genes related to different dis-
eases [9].As methodologies progress, network medicine
has the potential to capture the molecular complexity of
human disease while offering computational methods to
discern how such complexity controls disease manifesta-
tions, prognosis, and therapy. Up to now, different types of
biological data have been used to study disease related
genes and complexes [10-12]. For example, Goh K., et al.,
[13] constructed a network that consisted of genes asso-
ciated with the same disease, while Tian W., et al., [14]
combined protein and genetic interactions with gene
expression correlation. Ulitsky I and Shamir R [15] also
combined interactions from published networks and yeast
two-hybrid experiments to identify the associations.
Analyses of recent research studies, according to CIPHER
[16], GeneWalker [17], PRINCE [18] and RWRH [19]
highlighted the associations that were derived directly
from protein interactions to more distant connections in
various ways. Even though genes causing similar diseases
lay close to one another in the network, these algorithms
did not take into account the fact that the majority of
genetic disorders tend to manifest only in a single or a few
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tissues [13,20]. Tissue specificity is an important aspect of
many genetic diseases, reflecting the potentially different
roles of proteins and pathways in diverse cell lineages. In
the context of genetic disorders, even though the underly-
ing harmful mutation can exist in all the cells in the
human body, it most often wreaks havoc only in a few tis-
sues. This tissue selectivity will appear due to the differ-
ences in the functionality of the mutated protein within
these tissues, its tissue-specific interacting proteins, its
abundance and the abundance of its inter-actors. Hence,
the purpose of this study is to investigate whether a tissue
specific network was a better representation for the actual
disease-related tissue, which yields to more accurate prior-
itizations of the disease-gene associations.
Some research has been carried out by constructing tis-
sue specific networks to detect diseases through the
Bayesian structure learning algorithms [21]. But Bayesian
structure learning algorithms had three major shortcom-
ings, that is, the high computational cost, inefficiency in
exploring qualitative knowledge, and the inability to
reconstruct phenotype specific gene network. Others [22]
analyzed human PPIs in a tissue-specific context, showing
that many housekeeping proteins interact with highly
tissue-specific proteins, which in turn implies that house-
keeping proteins may have tissue-specific roles. This ana-
lysis was taken a step further by Emig and Albrecht [23]
who identified the functional differences between tissues,
showing that tissue-specific protein interactions are often
involved in transmembrane transport and receptor
activation.
This study therefore seeks to construct tissue-specific
gene-gene networks for a particular query disease and try
to match these networks with the similar phenotype
details to predict new disease-gene associations. The novel
tissue-specific gene-gene network construction method
called the tissue-specified genes (TSG) method would be
used to initially identify the tissues mainly affecting the
query disease and secondly the gene expression details of
the tissues would be used to construct tissue-specific
gene-gene networks. Created tissue-specific networks
would be used with the most nearest phenotype details of
the query disease to predict gene-disease associations. The
original Katz method has been modified and used as the
primary method of prioritizing disease genes by using tis-
sue-specific gene-gene networks. The novel tissue-specific
gene-gene network construction method is described in
details in the methodology section.
Methods
Tissue specific gene expression
Gene expression profiles have been widely used with
protein interaction networks to identify protein com-
plexes, predict protein functions, construct dynamic pro-
tein interaction networks, and discover disease-related
genes [24-26]. In this research, the human body index-
transcriptional profiling of tissue-specific gene expression
data set was downloaded from the gene expression omni-
bus (GEO) for GSE 7307 series [27] to predict disease
genes. The dataset consisted of a total of 677 samples,
representing over 90 distinct tissue types. Normal and dis-
eased human tissues were profiled for gene expression
using the Affymetrix U133 plus 2.0 arrays. Based on the
case studies which has used in this study, detailed gene-
expressions of 7 tissues were selected.
Disease-tissue relationship
The relationships between diseases and tissues were con-
sidered from the work by Lage et al [28] who estimated
the association of a tissue and a disease by measuring
their co-occurrence in PubMed abstracts. It has created a
disease-tissue co-variation matrix of high-confidence
associations of >1,000 diseases to 73 tissues.
Selection of tissue-specific gene interaction pairs
After identifying the tissues related to each query disease
gene expression, details of these tissues were downloaded
from GEO in the national center for biotechnology infor-
mation (NCBI) website. Using these genes expression
details of each query disease, Pearson correlation coeffi-
cient (PCC) was calculated [29-31] for each gene-gene
interaction in the gene-gene network.
A separate tissue specific gene-gene networks was con-
structed for each tissue that was related to the query dis-
ease by considering the PCC values for each gene-gene
interaction. The interactions that have PCC values more
than the threshold value were considered for tissue speci-
fic gene-gene network and others were removed from the
gene-gene network.
Weighted TSG network
After the creation of the tissue-specified genes (TSG) net-
work for each tissue, each interaction was weighed by con-
sidering the relationship between gene and different
phenotypes along with gene expression details of each
query disease. The weight of each interaction in the novel
network was calculated from equation (1).






+ (1 − α)PCC (1)
From the first part of the equation the co-occurrence of
phenotypes with less annotated genes that gave more
weight than well-studied, [23] broadly-defined phenotypes
are shown. Therefore in the equation, aik= 1 if gene i has
phenotype k and aik = 0 otherwise, and Nk is the number
of genes involved in the specific phenotype k; and n is
the total number of phenotypes. In the second part of
the equation it emphasis on the tissue-specificity of the
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interaction by incorporating PCC value. Hence, the
weight represents how each interaction in the tissue spe-
cified gene-gene network reacts to different phenotypes
while considering tissue-specificity. The phenotypes used
for the calculation are similar phenotypes to the query
disease. The similarities between phenotypes were
obtained using the matrix introduced by van Driel et al
[32], who used the anatomy (A) and the disease (C) sec-
tions of the medical subject headings vocabulary (MeSH)
to extract terms from online Mendelian inheritance in
man (OMIM) to identify similar diseases. Finally, a ∈ 0
[1] is a parameter controlling the relative importance of
the phenotype vs. the PCC value.
Construction of gene-phenotype network
To construct the gene-phenotype bipartite network for
each tissue type for the specific disease the following
method was used. The gene-phenotype association matrix
was constructed where, pi ∈ R|g|×|pi|, such that (Pi)gp = 1 if
gene g is associated with phenotype p or 0 otherwise. For
the matrix the phenotypes that were selected were similar
to phenotypes for the query disease. In order to find the
most similar phenotypes, the text mining method MimMi-
ner was used [32].
Construction of phenotype-phenotype network
Separate phenotype-phenotype matrices were constructed
for each query disease. To select the most similar pheno-
types for the query disease the MimMiner approach was
utilized [32].
Implementation of prioritization methods on TSG
network
Random Walks with Restart on Heterogeneous network
[19], PRINCE [18] and ProSim [33] methods were used as
prioritization methods that accepted TSG networks.
During the implementation of each method the entire
gene-gene network was sub divided into several tissues-
specified gene-gene networks depending on the query
disease. Then the algorithm was executed with each sub
network separately and the final results were merged from
the result of each sub network.
Random Walks with Restart on Heterogeneous network
Random Walks with Restart on Heterogeneous net-
work (RWRH) is an algorithm for predicting gene-dis-
ease associations proposed by Li and Patra. RWRH
performs a random walk on a heterogeneous network
of gene interactions and human diseases [19]. The ran-
dom walk is started from a set of seed nodes, which
for a phenotype p is the set of genes known to be
associated with p, and gene nodes are ranked by the
probability that a random walker is at a given gene,
under the steady state distribution for the random







where G is the entire gene-gene interactions matrix, Q is
the phenotype-phenotype similarity matrix, and λis the
probability that the random walker jumps from a gene
node to a phenotype node (or vice versa).
PRINCE and ProSim
PRINCE [18] and ProSim [33] are other graph-based
methods that can be thought of as a special case of
RWRH. In both methods random walk is used over the
protein-protein interaction network instead of the hetero-
geneous network. Phenotype similarity is used as the
restart vector in PRINCE [18] and the combination of phe-
notype similarity and protein proximity is used as the
restart vector for ProSim method [33]. For the research
experiment PRINCE algorithm has been changed where
protein-protein network is replaced by the tissue-specific
gene-gene network for a particular disease. The ProSim
method is changed where gene-gene network is con-
structed by considering three features: Pearson correlation
coefficient of tissue specific gene expression details of each
query disease, gene’s small world clustering coefficient and
subcellular localization details of each protein-protein
interaction. For both methods the final equation remains
same for our experiment.
Data sources
The data was downloaded from the following data
sources.
Gene-gene network: HPRD database was downloaded
from [34]. The edges in the HPRD network are un-
weighted. This protein-protein network was used to create
the gene-gene network.
Phenotype-phenotype network: with the use of OMIM
phenotypes, the similarity matrix will be calculated
using the MinMiner introduced by van Driel [32].
Results and discussion
Construction of tissue-specific gene-gene networkSix
case studies were studied, in order to measure the effec-
tiveness of the tissue specific details of each query dis-
ease, to predict disease genes. The selected cases
included; Breast Cancer (MIM: 114480), Colorectal
Cancer (MIM: 114500), Prostate Cancer (MIM: 176807),
Lung Cancer (MIM: 211980), Alzheimer (MIM: 104300)
and Diabetes Mellitus (MIM: 125853).
In order to identify the disease-tissue associations
research work carried out by [28] was used. According
to the study of Lagea, et al [28] a matrix was generated
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computationally which showed the relationship between
different tissues and diseases. Systematic analysis was
done between tissue-specific gene expression and patho-
logical manifestations in many human diseases and can-
cers. The diseases were systematically mapped to tissues
they affect from disease-relevant literature in PubMed
and used to create a disease-tissue co-variation matrix
of high-confidence associations of > 1,000 diseases to 73
tissues. From the results breast cancer (MIM: 114480),
ovary, prostate and skin tissues were identified as the
most prominent tissues affected by the disease. For Col-
orectal cancer (MIM: 114500), liver, lungs and ovary tis-
sues were responsible whiles for Diabetes mellitus
(MIM: 125853), liver and pancreatic islets tissues were
much prominent for the disease. Whiles for Prostate
cancer (MIM: 176807) prostate and skin tissues are
more prominent and for lung cancer (MIM: 211980)
lung and skin tissues as well. Finally for Alzheimer dis-
ease (MIM: 104300), brain tissues are more affected
from the disease.
After identifying the tissues for each disease, the gene
expression details for each tissue sample were downloaded
from the NCBI website. This consisted of human tissues
measured in the Human Body Index Transcriptional. By
using these genes expression details of each tissue in each
query disease, PCC was calculated for the entire gene-gene
network. The relationship between the PCC values and the
amount of coverage within the entire gene-gene network
is shown in Figure 1. From Figure 1, it was observed that
more gene-gene interactions are covered if 0.2 was
selected as the threshold value for PCC which unfortu-
nately, will reduce the prediction power of the final tissue-
specific gene-gene interaction network. Therefore consid-
ering the coverage and the effectiveness of predicting new
disease-gene associations 0.3 was selected as the threshold
value for PCC to create tissue-specific gene-gene
networks.
After removing the lower PCC value gene-gene interac-
tions from the network, all the remaining interactions
were weighted using equation (1). Testing was carried out
to find the best formulation between the phenotype and
the tissue gene expression values. In addition, testing was
repeated to check the most suitable parameter value for
the equation. Testing was based on the effectiveness of
predicting and detecting disease related genes from the
newly created tissue-specific gene-gene network. After a
series of testing the parameter a = 0.6 was finalized as the
best value.
Prediction of disease cause genes using Katz method
After constructing tissue-specific gene-gene networks,
Katz method was used to check the effectiveness of the
network in predicting disease genes. In order to prioritize
candidate disease genes, Katz method was used because its
application has been successfully tested for link prediction
in social networks [35]. Furthermore, the method is based
on integrating functional gene interaction networks with
phenotype data and computing a measure of similarity
based on walks of different lengths between gene and
phenotype node pairs. Hence in this research Katz method
has been used as the platform method to evaluate the per-
formance of each method of constructing tissue-specific
gene-gene networks in predicting disease genes.
By definition Katz measure is a graph-based method for
finding nodes similar to a given node in a network [36].
The research done by Singh-Blom, et al [37] applied Katz
method to recommending genes for a given phenotype or








Let G denote the gene-gene network, let P denote the
bipartite network between genes and phenotypes, and let
Q denote the phenotype-phenotype network. PT is the
transpose matrix of P. And the final Katz score matrix
SKatz (C) corresponding to similarities between gene
nodes and human disease nodes can be expressed as:
SKatzHs (c) = βPHs + β
2 (GPHs + PHsQHs) + β3
(
PPTPHs + G2PHs + GPHsQHs + PHsQ2Hs
)
(3)
where, PHs and QHs denote the gene-phenotype and
phenotype-phenotype networks of humans, respectively.
As well as P consist of phenotype information from
multiple species. Namely: pant, worm, fly, zebrafish, E.
coli, chicken, mouse and yeast phenotype information
are compared with human phenotype information. b is a
constant that dampens contribution from longer walks.
The research study has modified the Katz method in
Figure 1 Total coverage of the protein-protein network for
different PCC values. For breast cancer, colorectal cancer, diabetes
mellitus, prostate cancer, lung cancer and Alzheimer diseases how
many protein-protein interactions are covered for PCC values from
0.2 to 0.4.
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such a way that it will accept tissue-specific gene-gene
networks and it only considers gene-phenotype associa-
tions to human. Therefore the final Katz score matrix
SKatz (C) was calculated by considering the tissue details
along with the relationship between genes and pheno-
types. The equation is expressed as:
SKatz(c) = βP + β2 (GP + PQ) + β3
(
PPT + G2P + GPQ + PQ2
)
(4)
where, G, P and Q denote tissue-specified gene-gene
network, gene-phenotype network and phenotype-
phenotype network, respectively. (Construction of gene-
phenotype network and phenotype-phenotype network
is explained in the method section.) The algorithm para-
meter b will remain same as 10-6 and the number of
iteration to 3 [37]. From the final matrix values we are
able to predict candidate disease genes by considering
the tissue-specific details.
In order to check the performance of the TSG network,
it was evaluated with the generic protein-protein network
by considering the effectiveness of predicting known
disease genes as well as unknown disease genes. The pre-
diction rate of known and unknown disease genes for
breast cancer, colorectal cancer, diabetes mellitus, prostate
cancer, lung cancer and Alzheimer is shown in Figure 2.
From the result, breast cancer and colorectal cancer had a
higher rate in predicting known and unknown disease
genes than other diseases. Diabetes predictions showed
the lowest disease genes rate as compared with others.
According to the results highlighted, tissue-specific net-
work is reacting in higher rate in predicting known and
unknown disease genes for a particular disease than using
generic protein-protein network.
Furthermore, to justify the importance of using tissue-
specific gene-gene network instead of generic protein-
protein network for predicting and prioritizing disease
genes the generated TSG network was tested with three
other methods namely; ProSim [33], PRINCE [18] and
RWRH [19]. Leave-one-out cross validation was carried
out for each method to detect the capability of each
method in predicting known disease genes at the point
where generic PPI and TSG networks were used. With
each cross validation trial, a single seed gene related to
the query disease was removed and then each method
evaluated on its success of identifying and ranking the
removed seed gene. Figure 3, 4, 5 shows results of
leave-one-out cross validation as in columns. According
to Figure 3, 4, 5, for breast cancer by using tissue-speci-
fic gene-gene network it enables to predict true disease
genes the rate of 85%, 81% and 80% for ProSim,
PRINCE and RWRH methods, respectively. As well as
for Alzheimer disease the values change as 71%, 60%
and 61%, respectively. According to the results, we are
able to conclude that by using tissue-specific gene-gene
network it enables to predict more known disease genes
than using a generic PPI network.
Comparison with other network construction methods
In order to check the effectiveness of the novel method
of constructing tissue-specific gene-gene network it was
compared with three other methods. The methods
included; tissue-specific node-removal (TS-NR) and tis-
sue-specific edge-reweight (TS-ERW) methods designed
Figure 2 Prediction of known and unknown disease genes
between generic PPI and TSG network. Percentage of known
and unknown disease genes prediction by using generic PPI
network and TSG network for breast cancer, colorectal cancer,
prostate cancer, lung cancer, diabetes mellitus and Alzheimer
disease.
Figure 3 Percentage of true disease genes detection for
ProSim methods. Percentage values of true disease genes
detection by using generic PPI and TSG networks for ProSim
method. Testing is carried for breast cancer, colorectal cancer,
prostate cancer, lung cancer, diabetes mellitus and Alzheimer
disease separately.
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by Magger et al [38], and BlockRank method by Jiang et
al [39]. Basically node-removal tissue-specific PPI net-
work was derived by removing from the original PPI
network proteins that are not expressed in the relevant
tissue and all of the edges adjacent to them [38]. The
remaining edges were retained, along with their weights.
In an edge-reweight tissue-specific PPI network, the
confidence of each interaction represents the probability
that the interaction takes place within a given tissue.
This probability rw is calculated from the formula (5):
w′ij = P
(






) ∗ P (X (i, t) |t) ∗ P (X (j, t) |t) = wij ∗ rwn (5)
where wij is the original weight of the interaction and n
is the number (0-2) of lowly-expressed genes in tissue t
out of {Pi,Pj}. Thus, conversion of the generic PPI weight
to a tissue specific PPI weight using the edge reweight
method involves multiplying an edge’s weighted by rw if
one of its adjacent genes is not expressed in the tissue, and
by rw2 if neither of the edge’s adjacent genes are expressed
in the tissue [38]. Finally, BlockRank method [39] con-
structs the tissue-specific PPI network by considering only
the known disease genes and the 1-order neighbors of
these disease genes for a particular tissue related to each
disease. Thereafter, the topology of this PPI network can
be formulated as a square symmetric matrix L = (Lij)
(adjacent matrix of graph G), where Lij = 1 if protein pi
can interact with protein pj, and Lij = 0 otherwise. From
Markov chain perspective, the PPI network can be
explained by a probability transition matrix that one pro-
tein may interact with other proteins in this network with
a certain degree of probability. Thus, they obtained the
transition matrix of Markov model P = (Pij) from the





According to the research of Jiang, et al [39] this tran-
sition matrix has been used to predict candidate disease
genes. In order to check the effectiveness of each
method created tissue-specific protein-protein network
is forward to the tissue-specific Katz method to predict
disease-gene associations for each query disease. Addi-
tional file 1 illustrates the top ten genes predicted by
each method for each query disease. From the results it
concludes that TSG network enables to predict more
disease-gene associations than other three methods.
Evaluation process was carried out by conducting
leave-one-out cross validation technique for each
method. With each cross validation trial, it will hide all
associations between a given gene and diseases. There-
fore, validation will be done for all the known disease-
gene association as well as enabling the calculation of
the percentages of the true disease genes for each
method. By using this evaluation method it will find out
the best tissue-specific network to be used to predict
and detect known disease genes for a particular disease.
The percentage of true disease gene detection for each
method is shown in Table 1. TSG method was able to
predict disease genes; 76%, 73%, 66%, 78%, 75% and 80%
for breast cancer, colorectal cancer, prostate cancer,
lung cancer, diabetes mellitus and Alzheimer disease,
respectively.
We further inspect the mean enrichment value for
each method. In general, the mean enrichment formula
is: enrichment = 50 / (rank), for an interval of
Figure 4 Percentage of true disease genes detection for PRINCE
methods. Percentage values of true disease genes detection by
using generic PPI and TSG networks for PRINCE method. Testing is
carried for breast cancer, colorectal cancer, prostate cancer, lung
cancer, diabetes mellitus and Alzheimer disease separately.
Figure 5 Percentage of true disease genes detection for RWRH
methods. Percentage values of true disease genes detection by
using generic PPI and TSG networks for RWRH method. Testing is
carried for breast cancer, colorectal cancer, prostate cancer, lung
cancer, diabetes mellitus and Alzheimer disease separately.
Ganegoda et al. BMC Systems Biology 2014, 8(Suppl 3):S3
http://www.biomedcentral.com/1752-0509/8/S3/S3
Page 6 of 9
100 genes [40]. Based on ranking values, by using the
leave-one-out cross validation process, it was possible to
identify the rank of true disease genes for each method.
The final results are shown in Table 2. By analyzing the
results it is clear that our novel method comes first in
all case studies. BlockRank method comes in the second
place. For prostate cancer and diabetes mellitus NR
method is in third place and for other disease ERW
method comes on third.
Furthermore, ROC curves are drawn by considering
the sensitivity and specificity, measures for each method.
Sensitivity is defined as the percentage of true disease
genes that are ranked above a specified threshold while
specificity is defined as percentage of all non related dis-
ease genes that are ranked below a specified threshold.
In other words, ROC values can be interpreted as a plot
of the frequency of the disease genes above the thresh-
old versus the frequency of disease genes below the
threshold, where the threshold is a specific position in
the ranking. Thus it enables to calculate the sensitivity
and specificity for each case. In this scenario top 200
genes were taken into consideration. Hence the thresh-
old value is set as 200 for the study. For breast cancer
TSG method had the highest area coverage in ROC
curve as illustrate in Figure 6. ROC curves for other
case studies are given in additional file 2.
By considering the results, tissue-specific gene-gene
network predicts more new disease genes than the
generic protein-protein interaction network. By using the
TSG method it is predicting that NME1, MSH2, RAF1,
HDAC1 genes in ovary, prostate and skin tissues cause
breast cancer disease [41-43]. As well as STK11, HNF1A,
TSG101, KPNA2, MDM2, APEX1 genes in lungs, liver and
ovary tissues are also tumor progression genes for colorec-
tal cancer [44-46]. Furthermore INS, INSR, RXRA, MAPK8
genes in liver and pancreatic islets tissues is effective for
diabetes mellitus disease. For Alzheimer disease HTT,
PRNP, KAT5 genes in brain tissues are stimulating the dis-
ease [47-51]. TP53, AKT1, BARD, MUC4 genes [52-54] in
lung and skin tissues are effective for lung cancer and
TP53, NTRK1, BARD1, MDM4, E2F1 and CASP8 genes
[55-57] in prostate and skin tissues are tumor progression
genes for prostate cancer. As well as for breast cancer by
using the TSG method it enables to detect some genes
that help for breast cancer recovery. Namely: MDM4,
SMARCA4, E2F1 and SMAD3 [58,59] are some of the
tumor suppression genes that help for drug discovery and
therapy. BID and PEA15 are two genes [60,61] that detect
in lung cancer that help for drug discovery and therapy.
Conclusions
The purpose of the research was to find out the impor-
tance of using tissue-specific details in predicting dis-
ease-gene associations and to check whether it is
appropriate to use tissue-specific gene-gene network
instead of generic protein-protein network at all time in
predicting disease-gene associations.
A novel method was therefore proposed to construct
tissue-specific gene-gene networks. The performance of
Table 1 Percentage of true disease genes for various
methods.
Disease Name TSG NR ERW BlockRank
Breast Cancer 76% 42% 46% 55%
Colorectal Cancer 73% 52% 53% 61%
Prostate Cancer 66% 57% 55% 63%
Lung Cancer 78% 55% 57% 68%
Diabetes Mellitus 75% 58% 52% 66%
Alzheimer Disease 80% 68% 70% 76%
Percentage values of true disease genes detection for TSG, NR, ERW and
BlockRank methods. Testing is carried for breast cancer, colorectal cancer,
prostate cancer, lung cancer, diabetes mellitus and Alzheimer disease separately.
Table 2 Calculation of mean enrichment for various
methods.
Disease Name TSG NR ERW BlockRank
Breast Cancer 5.366 0.217 0.236 1.778
Colorectal Cancer 4.365 0.210 0.238 0.613
Prostate Cancer 1.590 0.417 0.389 1.089
Lung Cancer 10.694 1.082 1.096 3.596
Diabetes Mellitus 5.716 0.571 0.513 2.532
Alzheimer Disease 12.759 2.655 4.186 11.997
Mean enrichment values for TSG, NR, ERW and BlockRank method in the case
of breast cancer, colorectal cancer, prostate cancer, lung cancer, diabetes
mellitus and Alzheimer disease.
Figure 6 ROC curve for Breast cancer. Sensitivity and specificity
values for TSG, NR, ERW and BlockRank network in the case of
breast cancer.
Ganegoda et al. BMC Systems Biology 2014, 8(Suppl 3):S3
http://www.biomedcentral.com/1752-0509/8/S3/S3
Page 7 of 9
the proposed method was evaluated and compared with
three other methods, NR, ERW and BlockRank. The pro-
posed method outperforms above mentioned methods. At
the same time experiments were carried out to check the
effectiveness of using tissue-specific gene-gene networks
instead of generic protein-protein networks to predict dis-
ease-gene associations. With the results it was clear that
tissue-specific gene-gene networks performed better than
any other methods. It was also able to predict more
known and new disease-gene associations for a particular
disease. Hence the study was able to omit the use of gen-
eric protein-protein networks in predicting disease-gene
associations. Even though it outperforms existing methods
considered, further experiments need to be carried out to
tune its performance in prioritizing candidate genes.
Additional material
Additional File 1: Top ten genes. Title: Illustrate the top ten genes
predicted by NR, ERW and BlockRank method
Additional File 2: ROC curves. Title: ROC curves for other diseases.
(a) Colorectal cancer (b) lung cancer (c) prostate cancer (d) diabetes
mellitus (e) Alzheimer disease
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